Clinical Trial

Eltrombopag Combining Rituximab Versus Eltrombopag in the Management of Primary Immune Thrombocytopenia (ITP) in Adults

Recruiting Phase 4
View on ClinicalTrials.gov →
Summary
This multicenter randomized, open-label study aimed to compare the efficacy and safety of eltrombopag combining rituximab with eltrombopag in China adult ITP patients .This study was be conducted in adult ITP patients who had not responded to or had relapsed after previous treatment of ITP, including first line therapy and /or splenectomy.
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2020-08-15.
Trial Details
NCT Number NCT04518475
Lead Sponsor Institute of Hematology & Blood Diseases Hospital, China
Collaborators: The Second Affiliated Hospital of Kunming Medical University, Henan Cancer Hospital, Tianjin Medical University Second Hospital, The First Affiliated Hospital of Xiamen University, Affiliated Hospital of Nantong University
Conditions Primary Immune Thrombocytopenia (ITP)
Enrollment 224 participants
Start Date 2020-08-10
Primary Completion 2029-02-10 (estimated)
Study Completion 2030-08-10 (estimated)
Updated on ClinicalTrials.gov 2026-04-29